Tagged with Funding

Taiwan Wu Tsung-Tsong, Minister Without Portfolio of the Republic of China (Taiwan) supervises and coordinates Taiwan’s Biomedical Industry Innovation Program. In this exclusive interview, he documents his main priorities and the government’s unrivalled commitment to further enhancing the attractiveness of Taiwan’s biotech ecosystem and bolstering a win-win relationship between Taiwan, the…

Switzerland Switzerland has been long-established as one of the world’s most innovative countries and boasts a thriving ecosystem of startup biotechs. However, a slow and complex funding cycle means that an increasing number of Swiss biotechs are looking towards the US for funding; a trend that risks destabilising and weakening the…

Taiwan Chih-Kung Lee, Minister of Economic Affairs of the Republic of China (Taiwan) provides insights into Taiwan’s “new economic model” recently established by the new government to boost the country’s economic growth and ensure Taiwan renews its role as an innovation pioneer. He also documents the crucial role that the pharmaceutical…

Luxembourg Marc Schiltz reveals the ambitions of Luxembourg’s National Research Fund (FNR), how his team are encouraging integration and doing far more than just delivering funds to willing researchers. Over the past 5 years, you have taken it upon yourself to internally reorganize the Luxembourg National Research Fund ( FNR), sharpen…

Switzerland Walter Steinlin describes the Federal Commission of Technology and Innovation as a catalyst for turning research into innovation. Based in Bern, Switzerland, the commission funds research institutes in corporate projects, and provides mentorship and coaching support for start-ups. Could you give our international audience an overview of the Federal Commission…

Pharma Prof. Dr. István Vályi-Nagy, Director General of the United St. Istvan and St. Laszlo Hospitals, shares his insights on running one of the largest hospitals in Hungary and the challenges of chronic underfunding, while also providing his personal ambitions for the future state of Hungary’s healthcare system. Prior to becoming…

Pharma Laurent Levy, CEO at Nanobiotix, is leading the way in nanomedicine with new market-disruptive developments, establishing a growing presence in European and global research labs and pushing back the frontiers in healthcare, for the industry and for patients. What is the main focus of your work at Nanobiotix, a company you co-founded 12 years ago,…

Pharma Prof. Luigi Naldini, Director of TIGET, discusses the success of the institute and the groundbreaking partnerships it has formed with the pharmaceutical industry, as well as his ambitions for TIGET over the coming years. Prof. Naldini, the San Raffaele Telethon Institute for Gene Therapy was set up in 1995 as…

Pharma The CEO and CFO of SkylineDx talk about the company’s latest product, the MMprofiler™, a prognostic test to determine the level of risk of a multiple myeloma. Also discussed are SkylineDx’s future plans and how private funding capital is fostering a renaissance of the Dutch biotech sector. Personalized medicine will improve…

pharma Thomas Würdinger, winner of the 2014 Galenus prize, discusses his research team’s efforts to developing new treatment options and protocols for brain cancers, and the need for greater attention and investment in brain cancer treatment development, an area he identifies as the greatest unmet medical need in the field of…

Pharma The owner of Altis Biologics, Nick Duneas, illustrates the significance of the company’s flagship product, the Altis Osteogenic Bone Matrix (OBM) and how the company plans to commercialize the injectable bone graft substitute on a domestic and international scale moving forward. He also highlights how the Innovation Prize for Africa has…

Pharma The Netherlands Cancer Institute (NKI) has been at the international forefront of cancer research and treatment for more than 100 years. The director of research discusses the fields and collaborations the institute is currently focusing on and why funding to (blue-sky) research should be seen as an investment. What were…